Skip to content

Safety and vaildity of Castor branched aortic coated stent grafts or fenestrated endovascular aortic repair using physician-modified stent grafts treating thoracic aortic dissection involving the LSA: a prospective, single-center and non-randomized controlled trial

Safety and vaildity of Castor branched aortic coated stent grafts or fenestrated endovascular aortic repair using physician-modified stent grafts treating thoracic aortic dissection involving the LSA: a prospective, single-center and non-randomized controlled trial

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900021750
Enrollment
Unknown
Registered
2019-03-08
Start date
2019-03-08
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thoracic aortic dissection extending to left subclavian artery

Interventions

The experimental group:Castor branched aortic coated stent grafts
The control group:fenestrated endovascular aortic repair using physician -modified stent grafts

Sponsors

Tianjin Medical University General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients who aged over 18 years,male or non-pregnant female; 2. Patients who are diagnosed as aortic dissection; 3. Cases of proximal tears locate between 0-15mm distal to left subclavian artery (LSA) or retrograde dissection extend to the LSA; 4. Patient who could understand the purpose of the trial ,join by volunteer and sign informed consents; 5. Patients who will to be followed up according to the requirements of plan.

Exclusion criteria

Exclusion criteria: 1. The lesions involve zone 0 and zone 1; 2. Patients who have connective tissue disease. (e.g. Marfan syndrome); 3. Patients who have definite allergic history to nickel-titanium alloy materials; 4. Patients who have had or may have had severe reactions to contrast media; 5. Patients who are unable to follow up on time; 6. Patients whose Life expectancy are less than 12 months.

Design outcomes

Primary

MeasureTime frame
Treatment success rate at 12 months;

Countries

China

Contacts

Public ContactDai Xiangchen

Tianjin Medical University General Hospital

13302165917@163.com+86 13302165917

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026